Introduction – Addressing Core Industry Pain Points in Antibody Therapeutics Validation
The development of monoclonal antibodies (mAbs), bispecifics, and antibody-drug conjugates (ADCs) faces a persistent quality control challenge: reliably measuring complement-dependent cytotoxicity (CDC) activity early in the drug discovery pipeline. Traditional CDC assays suffer from high inter-laboratory variability, poor throughput, and difficulty in standardizing complement sources. Biopharmaceutical companies require outsourced Complement-dependent Cytotoxicity Testing Services that deliver reproducible membrane attack complex (MAC) quantification, compatibility with regulatory submissions, and scalability from lead optimization to lot release testing. The solution lies in platform-based service providers offering both common type and high-throughput CDC formats, integrated with flow cytometry or luminescence readouts, and aligned with ICH Q2(R2) validation guidelines.
According to the latest industry reference, Global Leading Market Research Publisher QYResearch announces the release of its latest report “Complement-dependent Cytotoxicity Testing Services – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Complement-dependent Cytotoxicity Testing Services market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5985559/complement-dependent-cytotoxicity-testing-services
Market Sizing and Recent Trajectory (2025–2032 Initial Estimates)
The global market for Complement-dependent Cytotoxicity Testing Services was estimated to be worth US218millionin2025andisprojectedtoreachUS218millionin2025andisprojectedtoreachUS 489 million by 2032, growing at a CAGR of 12.2% from 2026 to 2032. This growth is driven by three converging factors: (1) a 28% increase in global mAb and ADC INDs filed in 2025 compared to 2024, (2) the November 2025 FDA draft guidance on “Potency Assays for Monoclonal Antibodies,” which explicitly recommends CDC as a complementary mechanism-of-action assay for complement-recruiting antibodies, and (3) growing adoption of high-throughput CDC in CAR-T cell engineering to assess off-target complement activation.
Over the past six months (September 2025 – February 2026), four major contract research organizations (CROs) have expanded their CDC service offerings, with average capacity increasing from 500 to 2,000 samples per week. Notably, demand for CDC testing in Asian biopharma hubs (China, South Korea, Singapore) grew 34% YoY, driven by local biosimilar development programs requiring comparative CDC profiling against innovator products.
Technical Foundation – Understanding CDC Assay Mechanisms and Variability
Complement-dependent cytotoxicity assay (CDC) is an in vitro cell-based assay used to evaluate the cytotoxic ability of antibodies against target cells. CDC is based on the activation of the complement system and the formation of the membrane attack complex (MAC). In the CDC assay, target cells and antibodies are mixed, and then complement is added. Complement activation leads to the formation of MAC, resulting in the death of target cells. By measuring the survival rate of target cells or the release of molecules that represent cell death, the cytotoxic ability of the antibody can be evaluated. CDC is commonly used in the research and development of antibody drugs, vaccines, and immunotherapies, as well as in the evaluation of the efficacy of these treatments.
However, three technical challenges persist in outsourced CDC testing:
(a) Complement source variability – Rabbit complement (high potency but high background) versus human complement (physiologically relevant but donor-dependent). Leading service providers now offer normalized, pooled human complement with batch-specific CDC activity certificates.
(b) Endpoint readout heterogeneity – Traditional dye exclusion assays (e.g., trypan blue) have CVs of 15-20%, whereas flow cytometry-based viability or LDH release assays achieve CVs <8%. High-throughput platforms increasingly adopt time-resolved fluorescence (HTRF) or luminescent cell viability readouts.
(c) Cell line stability – CDC results vary significantly between suspension and adherent target cells, as well as between freshly isolated versus cryopreserved cells. Best-in-class service providers standardize on verified, low-passage cell banks with CD59 (complement regulatory protein) expression profiling.
Industry Disaggregation – Common Type vs. High-Throughput CDC Services
The Complement-dependent Cytotoxicity Testing Services market is segmented as below:
By Type (2025 Revenue Share):
- Common Type (manual or semi-automated, 96-well or 384-well formats) – 64% of market. Preferred for mechanistic studies, rare cell types, and regulatory dose-response characterization. Average turnaround: 10-14 business days.
- High-Throughput Type (fully automated liquid handling, 1536-well, multiplexed readouts) – 36% of market but growing at 18% CAGR (2026-2032). Essential for antibody library screening, epitope mapping, and biosimilar comparability panels. Average turnaround: 3-5 business days for up to 10,000 samples.
By Application (Demand Volume, 2026–2032 CAGR):
- Biopharmaceuticals – 13.8% (lead candidate screening, lot release potency, stability studies). Accounts for 58% of total service revenue.
- Cell Engineering – 16.5% (fastest-growing segment). CAR-T and TCR-T developers use CDC to assess complement-mediated clearance of engineered T cells.
- Medical Diagnosis – 9.2% (autoimmune disease monitoring, transplant compatibility).
- Medical Treatment – 7.5% (patient stratification for complement-targeting therapies).
- Others – 6.8% (vaccine quality control, veterinary biologics).
Selected Key Players and Recent Strategic Moves
- Creative Biolabs – Launched a “CDC Validation Package” (January 2026) including both rabbit and human complement parallel testing, with full ICH-compliant report.
- iQ Biosciences – Expanded high-throughput CDC capacity in San Diego (December 2025), adding a Beckman Coulter i7 automated workstation capable of 20,000 assays per day.
- Horizon Discovery – Introduced isogenic cell panel for CDC specificity testing (November 2025), using CRISPR-edited CD59 knockout and overexpression lines.
- Sino Biological, Inc. – Opened a CDC service center in Suzhou (February 2026) focused on bispecific antibody screening for the Asian market.
- GenScript ProBio – Received GLP certification for its CDC assay platform (October 2025), enabling regulatory submission support.
- Agilent – Integrated its xCELLigence RTCA technology with CDC protocols, providing real-time impedance-based cytotoxicity readouts without labeling.
- Sartorius – Launched an Incucyte-based CDC application module (September 2025) for live-cell imaging and automated MAC formation quantification.
Exclusive Industry Observation – The Upcoming “CDC Harmonization Standard”
Based on unpublished inter-laboratory comparison data from four global CROs (Q3–Q4 2025), CDC assay results for the same reference antibody (rituximab against Raji cells) varied by as much as 35% in EC50 values when using different complement lots, even within the same service provider. In response, the International Council for Harmonisation (ICH) is expected to release a new Q14 annex on “Biological Assay Harmonization” in mid-2026, which will include a dedicated section on CDC method transfer and complement qualification. This is likely to accelerate consolidation toward high-throughput, automated platforms and create a premium pricing tier (30-50% higher) for fully validated, transfer-ready CDC service packages.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
